Physical function declines in old age, portending disability, increased health expenditures, and mortality. Cellular senescence, leading to tissue dysfunction, may contribute to these consequences of aging, but whether senescence can directly drive agerelated pathology and be therapeutically targeted is still unclear. Here we demonstrate that transplanting relatively small numbers of senescent cells into young mice is sufficient to cause persistent physical dysfunction, as well as to spread cellular senescence to host tissues. Transplanting even fewer senescent cells had the same effect in older recipients and was accompanied by reduced survival, indicating the potency of senescent cells in shortening health-and lifespan. The senolytic cocktail, dasatinib plus quercetin, which causes selective elimination of senescent cells, decreased the number of naturally occurring senescent cells and their secretion of frailty-related proinflammatory cytokines in explants of human adipose tissue. Moreover, intermittent oral administration of senolytics to both senescent cell-transplanted young mice and naturally aged mice alleviated physical dysfunction and increased post-treatment survival by 36% while reducing mortality hazard to 65%. Our study provides proof-of-concept evidence that senescent cells can cause physical dysfunction and decreased survival even in young mice, while senolytics can enhance remaining health-and lifespan in old mice.
N ew approaches to treat age-related diseases (e.g., cardiovascular disease) may yield lifespan extension but potentially at the cost of extending late-life morbidity 1 . A major question in biology is whether interventions can be devised that enhance healthspan in tandem with increasing remaining lifespan so that the period of morbidity near the end of life is not increased 2 . Physical dysfunction and incapacity to respond to stresses 3, 4 become increasingly prevalent toward the end of life 5 , with up to 45% of people over the age of 85 being frail 6 . This physical dysfunction is associated with considerable morbidity, including decreased mobility and increased burden of age-related chronic diseases, loss of independence, nursing home and hospital admissions, and mortality 7 . The cellular pathogenesis of age-related physical dysfunction has not been fully elucidated, and there are currently no root causedirected, mechanism-based interventions for improving physical function in the elderly available for clinical application. Here we report a potential strategy for addressing this need: reducing senescent cell burden.
Cellular senescence is a cell fate involving extensive changes in gene expression and proliferative arrest. Senescence can be induced by such stresses as DNA damage, telomere shortening, oncogenic mutations, metabolic and mitochondrial dysfunction, and inflammation [8] [9] [10] . Senescent cell burden increases in multiple tissues with aging 11 , at sites of pathology in multiple chronic diseases, and after radiation or chemotherapy 12 . Senescent cells can secrete a range of proinflammatory cytokines, chemokines, proteases, and other factors; together, these are termed the senescenceassociated secretory phenotype (SASP) 13, 14 , which contributes to local and systemic dysfunction with aging and in a number of diseases [15] [16] [17] [18] [19] [20] [21] . A month or more of continuous treatment with Janus kinase 1 (JAK1) and JAK2 inhibitors or rapamycin can enhance physical function in older mice 14, 22 . However, JAK1 and JAK2 inhibitors and rapamycin have an extensive range of effects on cellular function. Among these is reduced production of some SASP components. We hypothesized, on the basis of these points, that senescent cells might potentially contribute to age-related physical
Results
Transplanting small numbers of senescent cells is sufficient to induce physical dysfunction in young mice. To test whether senescent cells can directly cause physical dysfunction, we first transplanted senescent or control (nonsenescent) preadipocytes (also termed adipocyte progenitors or adipose-derived stem cells 23 ) isolated from luciferase-expressing transgenic (LUC + ) mice intraperitoneally into syngeneic, young (6-month-old) wild-type (WT) mice ( Fig. 1a ). We induced cellular senescence using 10 Gy radiation, which resulted in more than 85% of cells becoming senescent ( Supplementary Fig. 1a,b ). We transplanted preadipocytes because: (i) the SASP of radiation-induced senescent mouse preadipocytes ( Supplementary Fig. 1c,d ) resembles that of endogenous senescent cells with aging ( Supplementary Fig. 1e ) 20, 24 and in idiopathic pulmonary fibrosis 25 ; (ii) preadipocytes are less immunogenic or subject to rejection than other cell types 26 ; and (iii) these cells are arguably the most abundant type of progenitors in humans 27 that are subject to cellular senescence. We also used doxorubicin to induce senescence to ascertain whether the physiological impact of transplanted senescent cells is limited to the context of radiation-induced senescence: senescent cells induced by doxorubicin developed a SASP similar to that of radiation-induced senescent cells ( Supplementary Fig. 1f ).
Five days after intraperitoneal transplantation of senescent or control preadipocytes, the cells were mainly located in visceral fat (Fig. 1b,c and Supplementary Fig. 2a,b ). Both the senescent and control transplanted cells remained detectable through in vivo bioluminescence imaging (BLI) for up to 40 d following transplant ( Supplementary Fig. 2c ). Of note, we observed that senescent cells had higher luciferase activity than control cells, even though they were from the same LUC + transgenic mice ( Supplementary Fig. 2d ).
To determine whether the transplanted senescent cells induced physical dysfunction in these mice, as determined by criteria used in clinical practice 4 , we measured maximal walking speed (via RotaRod), muscle strength (via grip strength), physical endurance (via hanging test and treadmill), daily activity, food intake, and body weight. Previously healthy young adult mice transplanted with 10 6 senescent cells had significantly lower maximal walking speed, hanging endurance, and grip strength by 1 month after transplantation compared to mice transplanted with control cells (Fig. 1d-f and Supplementary Fig. 3a ). Transplanting the same number of control cells had no effect as compared to injecting PBS. Daily activity, treadmill performance, food intake, and body weight were not statistically different among groups (Fig. 1g-j ). Transplanting 0.5 × 10 6 senescent cells was sufficient to cause decreased grip strength ( Fig. 1f ) and maximal walking speed ( Supplementary  Fig. 3b in a dose-dependent manner. We estimate that 6-month-old mice have 7 × 10 9 -8 × 10 9 cells of all types and that the total cell number in intraperitoneal adipose tissue, where the transplanted cells were mainly located ( Supplementary Fig. 2b ), is ~3.5 × 10 8 -6 × 10 8 cells (Methods). Thus in young mice, if only 1 cell in the 7,000-15,000 (0.01-0.03%) throughout the body or 1 cell in 350 (0.28%) locally is a transplanted senescent cell, age-related impairment in physical function ensues. Reduced walking speed began as early as 2 weeks following a single implantation of senescent cells ( Supplementary Fig. 3c ) and persisted for up to 6 months ( Supplementary Fig. 3d ), yet the transplanted cells survived in vivo for only approximately 40 d, consistent with the possibility that senescent cells might induce senescence in normal host cells 28, 29 . We therefore tested whether senescent cells can indeed cause other cells to become senescent in vivo by transplanting constitutively LUC + senescent cells and determining whether senescence occurs in the LUCrecipients' tissue. Most of the transplanted LUC + senescent cells resided in visceral fat ( Supplementary Fig. 2b ). Two months after transplantation, we found more senescence-associated β -galactosidase (SA-β gal) + cells and higher cyclin-dependent kinase inhibitor 2 A (Cdkn2a; also known as p16 Ink4a ) expression in visceral adipose tissue from senescent cell-than control cell-transplanted mice (Fig. 1k ,l) beyond the time the transplanted senescent cells were present as reflected by luciferase signal ( Supplementary Fig. 2c ). Telomere-associated foci (TAFs) are sites of DNA damage within telomeres 30 . TAFs appear to be a more specific marker of senescence than some others, such as SA-β gal. Significantly more TAF + cells were found in visceral adipose tissue of mice that had been injected with senescent than control cells (Fig. 1m ). These TAF + cells were LUC -, indicating that they were the recipients' own cells and not transplanted cells. F4/80 + macrophage accumulation was not induced in adipose tissue by the intraperitoneal senescent cell transplantation ( Supplementary  Fig. 3e ,f). Consistent with spread of senescence not only locally but also to distant tissues, expression of the markers and mediators of senescence p16 Ink4a , tumor necrosis factor alpha (Tnfα), and interleukin 6 (Il6) was higher in the quadriceps muscles, a tissue where transplanted cells were not detected ( Supplementary Fig.  2b ), of senescent-than control-transplanted mice ( Supplementary  Fig. 4a ). Similarly to adipose tissue, F4/80 + macrophage accumulation was not induced in muscle by senescent cell transplantation ( Supplementary Fig. 4b ). Thus, senescence spreading may explain how a small number of transplanted SEN cells caused such profound, long-lasting, and deleterious systemic effects.
To further test whether SASP-related factors can contribute to induction of cellular senescence in vivo, we examined IL-10 knockout mice, which have a genetically induced premature proinflammatory phenotype that resembles the SASP and which also prematurely develop physical dysfunction reminiscent of human frailty 31 . We found that these mice do indeed have more senescent cells than WT controls, supporting the possibility that the SASP can induce senescence spreading in vivo ( Supplementary Fig. 5a -c).
Aging and high-fat diet exacerbate effects of senescent cell transplantation.
Because aging is associated with senescent cell accumulation 14 , we tested whether increased recipient age potentiates the effects of transplanting senescent cells. We transplanted 0.5 × 10 6 senescent or control preadipocytes into older (17-month-old) mice, so that 0.007% of all cells in the recipients were transplanted senescent or control cells, and 1 month later, we measured various parameters of physical function ( Fig. 2a ). We found that mice transplanted with senescent cells had lower maximal walking speed, hanging endurance, and grip strength than control mice ( Fig. 2b-d) . These findings were consistent across several independent cohorts of male ( Supplementary Fig. 6a -f) and female mice ( Supplementary  Fig. 6g -l). Body weight, treadmill performance, daily activity, and food intake were not statistically different after transplanting senescent cells into the older mice ( Fig. 2e-h ). Transplanting 0.5 × 10 6 senescent cells led to greater impairment in walking speed and hanging endurance in 17-month-old mice than 6-month-old mice ( Fig. 2i ), whereas other parameters showed no statistically significant difference. Notably, in the 17-month-old mice transplanted with senescent cells, survival for the following year was significantly lower than that of age-matched control mice, with a 5.2-fold higher risk of death (mortality hazard ratio, P = 0.006) ( Fig. 2j ). Tumor burden, disease burden at death, and causes of death were not significantly altered by transplantation with senescent cells compared to control cells ( Fig. 2k,l ), suggesting that a small number of senescent cells may shorten survival through a general process, such as hastening the progression of aging, rather than by inducing any one individual disease or a few individual diseases. Thus, augmenting senescent cell burden induces physical dysfunction, more so in middle-aged than younger individuals, and increases mortality.
To determine whether augmenting senescent cell burden reduces resilience in the face of high fat intake, which is a metabolic stress known to promote senescent cell accumulation 32 , senescent or control preadipocytes were transplanted into 8-month-old nonobese mice, which were then fed a high-fat diet (HFD) for 1 month, followed by measurements of physical function (Fig. 3a) . The HFDfed mice transplanted with 0.4 × 10 6 senescent cells had lower maximal walking speed, hanging endurance, grip strength, daily activity, and food intake compared to HFD-fed mice transplanted with 0.4 × 10 6 control cells ( Fig. 3b-f ). Body weight and treadmill performance were not statistically different ( Fig. 3g,h) . Senescent cell-transplanted mice on a HFD had more impairment in walking speed and hanging endurance than age-matched transplanted mice on a normal chow diet (NCD), whereas other parameters were not statistically significantly changed ( Fig. 3i ). Collectively, these data indicate that transplanting small numbers of senescent cells causes greater systemic dysfunction in older individuals or in the context of metabolic stress.
To test whether the physical dysfunction in mice transplanted with senescent cells was due to transplant rejection, we transplanted mice with autologous ear fibroblasts in which senescence had been induced by 10 Gy radiation 16 versus sham-radiated control cells. Senescent fibroblasts 16 have a similar SASP to senescent preadipocytes ( Supplementary Fig. 1c ). We transplanted 10 6 senescent or control cells back into the same mice from which the ear fibroblasts had been isolated, and these mice were put on a HFD for 1 month (Fig. 3j ). Transplanting autologous senescent ear fibroblasts intraperitoneally, compared to control cells, led to impaired maximal walking speed, hanging endurance, and grip strength ( Fig. 3k-q) , as had occurred after transplanting nonautologous senescent preadipocytes. Moreover, we transplanted radiationinduced senescent primary human preadipocytes (characterized in ref. 14 ) versus sham-radiated control cells into severe combined immunodeficiency-beige (SCID-beige) mice with impaired T cell, B cell, and natural killer cell function 33 . Similarly to the effect of mouse senescent cells on immunocompetent mice, we found that physical function was impaired in the immune-deficient mice transplanted with the human senescent cells compared to those treated with control cells or with PBS ( Supplementary Fig. 7 ). Combined with our finding that senescent and control cells persisted for the same amount of time after transplantation ( Supplementary Fig. 2c ), these data support the possibility that physical dysfunction did not arise principally as a consequence of transplant immune rejection or in response to a particular type of senescent cell.
Dasatinib plus quercetin reduces senescent cell burden and decreases proinflammatory cytokine secretion in human adipose tissue.
In light of our finding that senescent cells cause physical dysfunction and shorten survival, senolytic agents, which can selectively eliminate senescent cells, might be an approach for enhancing healthspan in old individuals. Senolytic drugs have been reported to alleviate a variety of age-related disorders (reviewed in ref. 34 ). These agents were originally selected on the basis of their ability to transiently disable the senescence-associated antiapoptotic pathways (SCAPs) that protect senescent cells from their proapoptotic microenvironment 35 . However, the efficacy of senolytics in human tissues remains unclear. To begin the process of gauging the translational potential of this approach, we determined whether the combination of dasatinib plus quercetin (D + Q), the first senolytics reported 35 , is effective in a human tissue. We did so using freshly isolated human omental adipose tissue obtained from obese individuals (body mass index (BMI), 45.5 ± 9.1 kg/m 2 ; age, 45.7 ± 8.3 years), as obesity is associated with senescent cell accumulation 27, 32 . The surgically excised explants, which indeed contained naturally occurring senescent cells ( Supplementary Fig. 8a ), were immediately treated with D + Q (1 µ M + 20 µ M) or vehicle for 48 h (Fig. 4a ). The explants treated with D + Q had significantly less TAF + , p16 INK4A-hi , and SA-β gal + cells ( Fig. 4b-d ) and also more cells undergoing apoptosis ( Fig. 4e and Supplementary Fig. 8b ) compared to vehicle-treated explants from the same subjects. Forty-eight hours of treatment with vehicle did not affect total and senescent cell numbers in these adipose tissue explants ( Supplementary Fig. 8c ). Notably, expression levels of the three senescence markers TAF, p16 INK4A , and SA-β gal correlated with each other ( Supplementary Fig. 8d ).
We next examined whether D + Q had acute effects on macrophages in these explants. We costained for p16 INK4A and F4/80 (EMR1 in humans). Only the p16 INK4A+ ;F4/80(EMR1)cell population was lower in the explants treated with D + Q than in those treated with vehicle, whereas the numbers of p16 INK4A+ ;F4/80(EMR1) + or p16 INK4A-;F4/80(EMR1) + cells were not significantly affected ( Supplementary Fig. 9a ). In addition, expression of CD68, another , treadmill endurance (f), daily activity (g), and food intake (h) of 17-month-old male C57BL/6 mice at 1 month after being injected with 0.5 × 10 6 senescent or control preadipocytes (n = 8 mice for both groups). i, Percent changes in RotaRod (left; in 6-month-old mice, n = 21 for both SEN and CON; in 17-month-old mice, n = 22 for SEN and n = 20 for CON) and hanging test (right; in 6-month-old mice, n = 6 for both SEN and CON; in 17-month-old mice, n = 8 for both SEN and CON) scores for mice transplanted with 0.5 × 10 6 senescent cells relative to the average of mice transplanted with 0.5 × 10 6 control cells at both ages. Results are shown as box-and-whisker plots, where a box extends from the 25th to 75th percentile with the median shown as a line in the middle, and whiskers indicate the smallest and largest values. j, One-year-survival curves of 17-month-old nontransplanted mice (n = 33 mice, N/A) and mice transplanted with 0.5 × 10 6 senescent (n = 23 SEN mice) or control (n = 24 CON mice) preadipocytes. k, Quantification of tumor burden (left), disease burden (middle), and inflammation at death (right) (shown as means ± s.e.m.) after transplanting senescent or control cells (n = 10 SEN mice, n = 7 CON mice). l, Causes of death in transplanted mice (n = 10 SEN mice, n = 7 CON mice). *P < 0.05; two-tailed unpaired Student's t-test (b-i,k), Cox proportional hazard regression model (j) and chi-square and Fisher's exact tests (l).
macrophage marker was not altered acutely by D + Q in the adipose tissue explants ( Supplementary Fig. 9b ). These data suggest that D + Q treatment has little direct effect on macrophages, including p16 INK4A+ macrophages. Senescent preadipocytes produce a variety of proinflammatory cytokines 14 and can also induce cytokine production by adipose tissue in vitro ( Supplementary Fig. 10 ), potentially leading to amplification of adipose tissue inflammation. To test whether D + Q decreases cytokine secretion by adipose tissue from obese individuals, we treated explants with D + Q or vehicle for 48 h and then washed the explants. Conditioned medium (CM) was collected in the absence of drugs over the next 24 h. We measured secreted protein levels in CM after D + Q treatment and found less secretion of the key SASP components 14 IL-6, IL-8, monocyte chemotactic protein 1 (MCP-1), plasminogen activator inhibitor 1 (PAI-1), and granulocyte macrophage colony-stimulating factor (GM-CSF) in CM from the D + Q group than from the vehicle group, whereas two non-SASP-related factors, IL-10 and interferon (IFN)-γ (ref. 14 ) , were not statistically significantly altered ( Fig. 4f and Supplementary  Fig. 11a ). Furthermore, secretion of two adipokines, adiponectin and adipsin (markers of adipose tissue function 36 ), were not lower in the D + Q group, excluding a nonspecific effect of D + Q on protein secretion or overall cell viability ( Fig. 4f ). D + Q increased expression of peroxisome proliferator-activated receptor γ (PPARγ ) and
CEBPα , two key transcription factors that are required for adipose tissue function through regulating adipogenesis and adipose tissue insulin responsiveness 15, 37 (Fig. 4g ). This parallels the induction of these key adipogenic factors that we previously reported after targeting cellular senescence either by clearing senescent cells genetically from transgenic INK-ATTAC mice or inhibiting the SASP 15 . D + Q reduced cytokine production more extensively in the human adipose tissue explants than either D or Q alone ( Supplementary  Fig. 11b ), consistent with the finding that D + Q target a broader range of senescent cells than D or Q alone 35 . Of note, increases in IL-6 (ref. 38, 39 ), MCP-1 (ref. 40, 41 ) , and p16 INK4A (ref. 42, 43 ) are associated with frailty in humans. Thus, it appears that D + Q can kill naturally occurring human senescent cells and can attenuate secretion of inflammatory cytokines associated with human age-related frailty.
Eliminating senescent cells both prevents and alleviates physical dysfunction induced by senescent cell transplantation.
We tested whether D + Q kills transplanted senescent cells in vivo by injecting LUC + senescent or control preadipocytes intraperitoneally into non-luciferase-expressing WT mice. The mice were treated immediately after transplantation with D + Q or vehicle for 3 d (Fig. 5a ). Luminescence was significantly lower in senescent cell-transplanted mice treated with D + Q than in vehicle-treated mice, and no difference was observed following treatment of mice transplanted with LUC + control cells (Fig. 5b,c) , confirming D + Q are senolytic in vivo. These findings further support the conclusion that D + Q can selectively kill senescent cells. We ascertained whether clearing transplanted senescent cells using D + Q prevents development of physical dysfunction. Treating young mice with D + Q at the time of senescent cell transplantation for 3 d attenuated the deteriorations in walking speed, hanging endurance, and grip strength that occurred 1 month later in vehicle-treated senescent cell-transplanted mice, consistent with the possibility that D + Q treatment is sufficient to prevent the physical dysfunction caused by senescent cells (Fig. 5d-f ). D + Q also alleviated the physical dysfunction that occurred in mice at 5 weeks following senescent cell transplantation (Fig. 5g ). In the senescent cell-transplanted mice, a single 5-d course of D + Q treatment improved physical function compared to vehicle ( Fig. 5h-j) . This improvement was evident at 2 weeks after D + Q treatment and lasted for several months ( Supplementary Fig. 12a ). At these two time points of D + Q administration (immediately versus 5 weeks after transplantation), the beneficial effects of D + Q were comparable. Therefore, we speculate that the time of administration of senolytics may be flexible, potentially increasing their clinical utility. Because D + Q have elimination half-lives of < 12 h 44 sustained improvement in physical function following a single course of D + Q treatment does not involve mechanisms that require continuous presence of the drugs, such as occupancy of a receptor or sustained effects on an enzyme. These findings suggest that the senolytic activity of D + Q is sufficient to attenuate senescent cellinduced physical dysfunction. 25, 35, [46] [47] [48] . To test the role of senescent cells in physical dysfunction in aged mice, we treated 20-month-old nontransplanted, WT mice with D + Q or vehicle intermittently for 4 months (Fig. 6a ). D + Q alleviated physical dysfunction-maximal walking speed, hanging endurance, grip strength, treadmill endurance, and daily activity were higher in mice treated with D + Q than in those treated with vehicle ( Fig.  6b-g) . Food intake also tended to be higher in D + Q-treated mice (P = 0.074; Fig. 6h ). Moreover, the expression of several key SASP components was lower in the visceral adipose tissue from aged mice treated with D + Q than in vehicle-treated mice (Fig. 6i) , concordant with lower secretion of SASP factors by human adipose tissue treated with D + Q (Fig. 4g) .
Clearance of senescent cells alleviates physical dysfunction and increases late-life survival without extending morbidity in aged mice. D + Q have been shown to decrease senescent cells in a variety of tissues in different situations, including aging
To further test the possibility that there could be a causal role for senescent cells in inducing physical dysfunction, we used the transgenic INK-ATTAC mouse model, in which endogenous p16 INK4A+ cells, many of which are senescent, can be genetically cleared by activating the caspase-8 moiety of ATTAC, which is expressed only in p16 INK4A+ cells 49 (Methods). Consistent with our findings in mice treated with D + Q, reducing the burden of p16 INK4A-hi cells in 26-to 28-month-old INK-ATTAC +/mice also alleviated physical dysfunction ( Supplementary Fig. 12b-f ).
Testosterone has been reported to alleviate physical dysfunction with aging 50 . To test whether testosterone levels are affected by D + Q, we measured circulating testosterone levels in two cohorts and found no statistically significant differences between the vehicle and D + Q groups ( Supplementary Fig. 13 ). This appears to rule out the potential explanation that improvement of physical function is due to increased testosterone induced by senolytics.
Next, we tested whether eliminating senescent cells using a potentially translatable approach, intermittent treatment with senolytics beginning at very old age, extends remaining lifespan in WT mice (Fig. 6j ). Remarkably, mice treated with biweekly administration of D + Q starting at 24-27 months of age (equivalent to a human age of 75-90 years) had a 36% higher median post-treatment lifespan and a lower mortality hazard, 64.9% (P = 0.01), than the vehicle group (Fig. 6k,l and Supplementary Fig. 14a,b) , indicating that senolytics can reduce risk of death in old mice.
To test whether this reduced mortality in old mice comes at the cost of an increased period of late-life morbidity, we assessed physical function in mice treated with D + Q or vehicle monthly until death. Despite the longer remaining lifespan in the D + Q-treated mice, physical function in the last 2 months of life was not lower than that of vehicle-treated mice in males and females ( Fig. 6m and Supplementary Fig. 14c,d) . At autopsy, the prevalence of several age-related diseases, tumor burden, and cause of death were not statistically different between D + Q-and vehicle-treated mice in males and females ( Fig. 6n and Supplementary Fig. 15 ). Thus, orally active senolytic drugs, which reduce the burden of senescent and possibly other cells that have exaggerated inflammatory cytokine production coupled with dependence on prosurvival SCAP pathways, can increase post-treatment lifespan without causing prolonged morbidity in mice, even when administered late in life.
Discussion
Our study shows that health-and lifespan are curtailed by increased senescent cell abundance and, conversely, are enhanced by reducing proinflammatory, SCAP-dependent senescent cell burden in mice, even late in life. Collectively, evidence for a causal role of such senescent cells in physical dysfunction satisfies a modified set of Koch's postulates 34 : (i) senescent cell burden 14 and physical dysfunction 5 are associated with each other and with aging; (ii) transplanting small numbers of senescent cells into young mice that have few endogenous senescent cells is sufficient to cause physical dysfunction that lasts for months; (iii) senolytics prevent and alleviate this senescent cell transplantation-induced physical dysfunction in young mice; (iv) clearing senescent cells alleviates physical dysfunction and increases remaining lifespan in old mice; and (v) locally inducing senescence in the lung impaired physical function, and clearing senescent cells improved physical function in a bleomycin-induced pulmonary fibrosis mouse model 25 . Notably, we determined that the total cell number in recipient adipose tissue is approximately 350 million. Several studies have shown that the percentage of senescent cells in adipose tissue from aged animals can be up to 2-10% (refs 14, 15, 20 ) , indicating that there might be at least 7 million endogenous senescent cells in adipose tissue of aged mice. Although other mechanisms might contribute, one reason why such a small number (0.5-1 million) of transplanted senescent cells could cause systemic dysfunction is spread of senescence and inflammation locally and to distant tissues. We used preadipocytes for transplantation, as these cells appear to be less susceptible to immune rejection than other cell types 26 reason for their increasing clinical use in cell transplantation studies. To further test whether there is a role of immune rejection in the physical dysfunction caused by senescent cell transplantation, we performed autologous transplantation, and we also transplanted human senescent cells into immunodeficient (SCID-beige) mice. Senescent cells induced essentially identical physical dysfunction in both of these settings in which immune rejection is greatly reduced. These points, together with our finding that transplanted senescent and control cells disappear at the same rate following transplantation, plus the long-lasting phenotypes caused by transplanting senescent cells, indicate that immune-rejection or transient 'sickness' caused by transplantation might not be a primary cause for the physical dysfunction we found. The SCID-beige mouse senescent cell-transplantation model could pave the way for testing the effects of other senescent cell types that are more immunogenic than preadipocytes or autologous cells in future studies. We originally discovered that D + Q are senolytic agents by using a hypothesis-driven bioinformatics approach. This approach was based on the hypotheses that senescent cells depend on prosurvival pathways to defend themselves against their proapoptotic microenvironment and that disabling these pathways would therefore selectively kill senescent cells 35 . That D + Q can specifically kill senescent cells in human adipose tissue is supported by the following evidence: (i) D + Q induce apoptosis only in senescent human cells, rather than in control cells in vitro 35 ; (ii) D + Q significantly decreased senescent cells as determined in three different assessments, whereas D + Q did not reduce the overall number of cells in adipose tissue; and (iii) secretion of two major adipokines was not reduced by D + Q, effectively ruling out nonspecific effects on secretion or cell viability. We believe that these data indicate that occurrence of nonspecific cellular toxicity occurs as a result of D + Q is unlikely. Of note, we showed the effectiveness of senolytics in targeting naturally occurring senescent cells in human adipose tissue explants collected from obese subjects. Although similar to aging, obesity is highly associated with increased senescent cell burden 27, 32 . In future studies, the efficacy of senolytics in tissues from older humans needs to be compared to that in explants from obese subjects.
We found that D + Q has little direct effect on macrophages. However, it is unlikely that the substantial reduction of proinflammatory cytokine secretion following D + Q was due to elimination of senescent cells alone. Interestingly, we found that senescent cells can induce adipose tissue cytokine production, potentially amplifying inflammation. By clearing senescent cells, this possible amplification of inflammation could be attenuated in adipose tissue, which includes macrophages. On the basis of these findings, we speculate that by decreasing senescent cell abundance, reduced inflammatory activity in adipose tissue could ensue and contribute to the reduction of inflammation after D + Q exposure, as well as to decreased spread of senescence.
Reducing p16 INK4A-hi cells, some of which are senescent, in INK-ATTAC transgenic mice starting from midadulthood (age 12 months) reportedly extends median lifespan 49 . In our study, administration of D + Q or AP20187 under the same conditions to WT and INK-ATTAC mice began at age 24-27 months. Unlike D + Q, AP20187 did not enhance late-life survival. One reason could be that senolytics act by disabling the SCAP, a mechanism of action that is distinct from that in INK-ATTAC mice, in which p16 INK4A-hi cells are targeted. We chose old age (24-27 months) rather than middle age (12 months) to start treatment for several reasons. First, 12-month-old mice are roughly equivalent to 40-year-old humans, and 24-month-old mice are equivalent to 75-year-old humans. We felt that beginning at 24 months of age is potentially a more translatable scenario. Second, AP20187 targets p16 INK4A+ cells, some of which are senescent, but others of which are not 51,52 (e.g., pancreatic β -cells, macrophages, etc.). Considering that 12-month-old mice have very few detectible senescent cells in adipose tissue, whereas these cells are abundant in 24-month-old mice 20 , beginning AP20187 administration at 12 months of age could have targeted a higher proportion of p16 INK4A+ cells that are not senescent than initiating treatment at 24 months of age, when senescent cells are readily detectible in multiple tissues. Third, treating INK-ATTAC mice from 12-month-old mice led to an increase in median rather than maximum survival. This is consistent with our finding that AP20187 did not detectibly increase late-life survival. On the other hand, we show here that by initiating senolytics in later life, late-life survival is actually increased.
Age-related diseases were delayed as a group in old male and female mice treated with D + Q compared to vehicle-treated controls. There was no one disease that was delayed or prevented that alone accounted for this increase in survival. In further support of the hypothesis that senescent cells participate in predisposition to age-related dysfunction, we found that the converse is also the case. Age-related diseases occurred earlier as a group in senescent cell-transplanted mice, coupled with shorter survival, than in control mice not transplanted with senescent cells. No one disease accounted for this decreased survival. These findings are consistent with the geroscience hypothesis: by targeting a fundamental aging process, such as cellular senescence, age-related disorders will be delayed as a group, with no one condition predominating.
Quercetin has been found to alleviate a variety of disorders through diverse mechanisms of action 53 , almost all of which have been studied with uninterrupted dosing, resulting in quercetin being continuously present. This is consistent with the presumption that quercetin acts on specific enzymes or pathways to achieve these effects. However, in our study, we administered D + Q intermittently. Dasatinib and quercetin both have short elimination half-lives 44, 45 , supporting the possibility that their beneficial effects on late-life function and survival were at least partially due to a mechanism that persists long after the drugs are no longer present, such as senescent cell elimination. Dasatinib can have side effects, occasionally including serious ones such as pulmonary edema, which can occur after 8-48 months of daily administration 54 . Although recognized side effects of drugs in mice often differ substantially from those in humans, in our study, mice given D + Q intermittently lived longer and had improved physical function compared to vehicle-treated mice. When they eventually died, the pathologies of D + Q-treated mice determined at autopsy and through histological analysis did not differ substantially from those of vehicle-treated mice. Possibly, intermittent treatment with senolytics may serve to reduce potential side effects 55 , an important consideration in the frail elderly, a population vulnerable to adverse drug reactions. We emphasize that preclinical studies to search for potential toxicities and optimized regimens are required before contemplating trials in relatively healthy humans. A search for possible side effects of senolytics as a class and of individual senolytics is especially important.
Our study provides proof-of-concept evidence indicating that targeting senescent cells can improve both health-and lifespan in mice. Because of the role of senescent cells in inducing physical dysfunction in mice demonstrated here (with some similarity to human frailty 4, 31, 56 ), senolytics might prove to be effective in alleviating physical dysfunction and resulting loss of independence in older human subjects, depending on whether these agents turn out to be safe and effective in clinical trials. Depending on the outcomes of such ongoing (ClinicalTrials.gov identifier: NCT02848131) and future preclinical and clinical studies, intermittent administration of senolytics, including newer agents such as optimized derivatives of D + Q, could possibly be useful in enhancing healthspan and remaining survival not only in older subjects, but also in other individuals, such as cancer survivors treated with senescence-inducing radiation or chemotherapy 57 .
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0092-9. day, mice ran on the treadmill at an initial speed of 5 m/min for 2 min, and then the speed was increased by 2 m/min every 2 min until the mice were exhausted. Exhaustion was defined as the inability to return onto the treadmill despite a mild electrical shock stimulus and mechanical prodding. Distance was recorded and total work (kJ) was calculated using the following formula: mass (kg) × g (9.8 m/s 2 ) × distance (m) × sin(5°).
Real-time PCR.
TRIzol was used to extract RNA from tissues. RNA was reversetranscribed to cDNA using a M-MLV Reverse Transcriptase kit (Thermo Fisher Scientific) following the manufacturer's instructions. TaqMan fast advanced master mix (Thermo Fisher Scientific) was used for real-time PCR. TATA-binding protein (TBP) was used as an internal control. Probes and primers (TBP, Mm01277042_ m1; IL-6, Mm00446191_m1; TNF-α , Mm00443260_g1; p16 Ink4a , Mm00494449_m1; p21 Cip1 , Mm04205640_g1) were purchased from Thermo Fisher Scientific.
Testosterone assay. Circulating testosterone was assayed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Agilent Technologies, Santa Clara, CA 95051). Intra-assay coefficients of variation (c.v.) were 7.4%, 6.1%, 9.0%, 2.3%, and 0.9% at 0.65, 4.3, 48, 118, and 832 ng/dl, respectively. Interassay c.v. values were 8.9%, 6.9%, 4.0%, 3.6%, and 3.5% at 0.69, 4.3, 45, 117, and 841 ng/dl, respectively.
Human adipose tissue explants. The protocol was approved by the Mayo Clinic Foundation Institutional Review Board for Human Research. Informed consent was obtained from all subjects. Human adipose tissue was resected during gastric bypass surgery from eight obese subjects. Two of the subjects were male, and six were female. The mean age of the subjects was 45.8 ± 8.2 years (mean ± s.d.; range, . Mean BMI was 45.5 ± 9.1 kg/m 2 (mean ± s.d.; range, . No subject was known to have a malignancy. Greater omental adipose tissue was obtained from each subject. Adipose tissue was cut into small pieces and washed with PBS three times. Adipose tissue was then cultured in medium containing 1 mM sodium pyruvate, 2 mM glutamine, MEM vitamins, MEM nonessential amino acids, and antibiotics with 20 µ M quercetin and 1 µ M dasatinib or DMSO. After 48 h, the adipose explants were washed three times with PBS. Aliquots of adipose tissue were fixed for immunostaining or SA-β gal assay. The rest of the tissue was maintained in the same medium without drugs for 24 h to collect CM for multiplex protein analysis. For Supplementary Fig. 10 , CM was collected from human senescent primary preadipocytes, control preadipocytes, and blank culture flasks containing no cells (Blank CM). senescent and control preadipocytes were obtained from the same donor. Human subcutaneous adipose tissue explants were obtained from a lean kidney donor (BMI, 26.5 kg/m 2 ; age, 43 years) and divided into pieces. These explants were incubated with senescent, control, or Blank CM for 24 h. Next, these explants were washed with PBS and then incubated with fresh medium for conditioning for another 24 h.
Multiplex protein analyses. Proinflammatory cytokine and chemokine protein levels in CM were measured using Luminex xMAP technology. The multiplexing analysis was performed using the Luminex 100 system (Luminex, Austin, TX) by Eve Technologies Corp. (Calgary, Alberta, Canada). Human multiplex kits were from Millipore (Billerica, MA).
SA-βgal assay and immunostaining.
Adipose tissue cellular SA-β gal activity was assayed as previously described 14 . TAF immunofluorescence in situ hybridization was performed as described previously 30 . Briefly, formalin-fixed, paraffinembedded (FFPE) adipose tissue blocks were cut into 5-µ m sections. Sections were deparaffinized with Histoclear (National Diagnostics, Charlotte, NC) and hydrated using an ethanol gradient. Antigen was retrieved by incubation in 0.01 M, pH 6.0 citrate buffer at 95 °C for 10 min. Slides were placed into blocking buffer (goat serum or horse serum 1:60 in 0.1% BSA in PBS) for 60 min at room temperature. Samples were further blocked with avidin-biotin (Vector Lab, Burlingame, CA) for 15 min at room temperature. Primary antibody (anti-γ H2AX 1:200, Cell Signaling, Danvers, MA, catalog no. 9718) was applied overnight at 4 °C in the blocking buffer. Washed slides were then incubated for 30 min with biotinylated, anti-rabbit secondary antibody (Vector Lab, catalog no. BA-1000). Finally, fluorescein-labeled avidin DCS (Vector Lab) was applied for 20 min. For luciferase costaining, a second primary antibody (anti-luciferase 1:500, Novusbio, Littleton, CO, catalog no. NB100-1677SS) was applied overnight at 4 °C in blocking buffer. Next, washed slides were incubated with secondary antibody (Alexa Fluor 647 1:500, Thermo Fisher Scientific, catalog no. A-21447). Telomeres were then stained by fluorescent in situ hybridization (FISH). Slides were fixed with 4% paraformaldehyde for 20 min, dehydrated in an alcohol gradient cascade, and denatured for 10 min at 80 °C in hybridization buffer (70% formamide (Sigma-Aldrich), 25 
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Replication
Describe whether the experimental findings were reliably reproduced.
All the key findings were reliably reproduced in several independent cohorts with large N's.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
We used baseline body weight to assign animals to experimental groups (to achieve similar body weight between groups), so only randomization (using a random number generator in Excel) within groups matched by body weight was conducted.
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Investigators were blinded to allocation during experiments and outcome assessments.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
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